Can Estradiol Cause High Blood Pressure?

Estradiol, the body’s primary natural estrogen, generally does not raise blood pressure and in many clinical settings modestly lowers it. The hormone promotes the release of nitric oxide in blood vessel walls, which relaxes arteries and improves blood flow. But the full picture is more complicated than a simple yes or no. The type of estrogen matters, the way it enters the body matters, the dose matters, and the state of your blood vessels when you start taking it matters. Under certain conditions, estrogen-containing medications can push blood pressure upward, sometimes significantly.

How Estradiol Relaxes Blood Vessels

The reason estradiol is often protective against high blood pressure comes down to what it does inside blood vessel walls. When estradiol binds to estrogen receptors on the cells lining your arteries, it triggers a chain of events that increases the production of nitric oxide, a molecule that tells the surrounding smooth muscle to relax. In laboratory studies, estradiol boosted the activity of the enzyme responsible for making nitric oxide by roughly two and a half times, and this effect required activation of the estrogen receptor to work.¹ The response is also remarkably fast. In endothelial cell experiments, estradiol increased the phosphorylation of the signaling protein Akt within a single minute, which then switched on nitric oxide production and dilated cerebral blood vessels under various flow conditions.²

Estradiol also has a metabolite called 2-methoxyestradiol that relaxes arterial smooth muscle through a nitric oxide-dependent pathway, though it works through a different mechanism than estradiol itself and does not rely on the estrogen receptor.³ The effect of estradiol on arteries is notably different from its effect on veins. In tissue from patients with atherosclerosis, estradiol caused relaxation in arteries but not in veins, and actually enhanced contractions to a vasoconstricting peptide in veins.⁴ This split behavior between arteries and veins may partly explain why estrogen therapy carries a risk for blood clots (a venous problem) while often being neutral or beneficial for arterial blood pressure.

Why Oral Contraceptives Are the Exception

If estradiol itself tends to lower blood pressure, why are birth control pills linked to hypertension? The answer lies in the type of estrogen used. Most combined oral contraceptives contain ethinylestradiol, a synthetic estrogen that behaves differently from the body’s own estradiol once it passes through the liver. High-dose synthetic estrogens stimulate the liver to produce more angiotensinogen, a protein that feeds into the renin-angiotensin-aldosterone system, which is one of the body’s main blood pressure control systems. The resulting increase in angiotensin II is enough to slightly reduce blood flow to the kidneys and increase sodium retention. In most women this produces a small, clinically unimportant rise in blood pressure, but in susceptible individuals the increase can be substantial.⁵

Epidemiological evidence has long supported a link between oral contraceptive use and blood pressure elevation, with the estrogenic component’s effect on the renin-angiotensin system thought to be the primary driver.⁶ The progestin paired with the estrogen also matters. A systematic review found that ethinylestradiol combined with gestodene raised blood pressure over six months of cyclic use, while ethinylestradiol combined with chlormadinone actually lowered it over two years.⁷ Newer formulations using natural estrogens rather than ethinylestradiol, or progestins with anti-mineralocorticoid properties like drospirenone, may reduce or even reverse the blood pressure effect.⁶

Patches Versus Pills in Menopause Therapy

For women using hormone therapy around menopause, one of the most consistent findings in the research is that how estradiol enters the body shapes its effect on blood pressure. Oral estrogens pass through the liver first, where they can increase angiotensinogen production. Transdermal estradiol, delivered through a skin patch or gel, enters the bloodstream directly and largely bypasses that liver effect.

In a review of large trials, oral hormone therapy had an essentially neutral effect on blood pressure in women with normal readings, and was also neutral in women who already had hypertension. Transdermal estradiol combined with micronized progesterone, by contrast, had a beneficial effect on blood pressure in women with normal readings and, at worst, a neutral effect in women with hypertension.⁸ A study using 24-hour ambulatory monitoring found that women on transdermal estrogen experienced drops in nighttime systolic pressure and in both daytime and nighttime diastolic pressure after six months. Women on oral estrogen did not show these drops on average, though more than a third of women in both groups had a statistically significant blood pressure increase, a reminder that individual responses vary widely.⁹

Overall, the evidence from ambulatory blood pressure monitoring and transdermal estrogen studies is more convincing and consistent in showing a positive effect on blood pressure control in postmenopausal women, whether or not they have hypertension. Adding a progestin generally does not interfere with the blood pressure effect of estrogen.¹⁰

Estradiol Can Actually Lower Blood Pressure After Menopause

A placebo-controlled crossover study in postmenopausal women using ambulatory monitoring found that estradiol, with or without progesterone, substantially lowered nighttime blood pressure compared with placebo. Nocturnal systolic pressure fell by about 6 mmHg and diastolic pressure by about 5 mmHg. The authors specifically noted that contrary to what is often assumed, estradiol did not raise blood pressure but rather lowered it.¹¹

A year-long randomized trial in hypertensive postmenopausal women using low-dose estradiol with dydrogesterone confirmed this direction. After twelve months, the hormone therapy group had statistically significant decreases in 24-hour mean arterial pressure, daytime diastolic pressure, and nighttime systolic and mean arterial pressure. The control group did not experience these drops.¹² These are not dramatic reductions, but they push back against the common worry that starting hormone therapy will drive blood pressure up.

When You Start Matters More Than Whether You Start

The timing hypothesis is one of the most important concepts in understanding estrogen’s cardiovascular effects. The idea is straightforward: estrogen’s effect on your blood vessels depends on the condition those vessels are in when you begin therapy. If arteries are still relatively healthy, estrogen tends to be protective. If atherosclerosis has already progressed, the benefit diminishes or may even reverse.

Animal studies provided some of the earliest clean evidence for this. In monkeys, hormone therapy slowed the progression of coronary artery atherosclerosis, but only when started soon after surgical menopause. When treatment was delayed until plaques had already become complex, the benefit was lost.¹³ In human studies, estrogen improved the ability of blood vessels to dilate more effectively in women within five years of menopause than in those who had been postmenopausal for longer. Among women farther from menopause, those who had previously used estrogen still responded better than those who had never used it.¹⁴

This means that the answer to whether estradiol will raise or lower your blood pressure partly depends on when you start it relative to menopause. A woman in her early fifties starting transdermal estradiol shortly after her final period is in a very different physiological situation from a woman in her mid-sixties starting oral conjugated estrogens a decade and a half later. Much of the negative data on estrogen and cardiovascular outcomes came from studies like the Women’s Health Initiative, which enrolled women whose average age was 63 and who were often many years past menopause.

Estradiol and Fluid Balance in the Kidneys

Beyond its direct effects on blood vessels, estradiol influences blood pressure through the kidneys. The kidney is a central player in long-term blood pressure regulation because it controls how much sodium and water your body retains. Estradiol modifies several of the kidney’s sodium-handling mechanisms through transporter regulation, adjusting salt and water conservation to support the fluid changes required during the menstrual cycle and pregnancy.¹⁵

One of the specific kidney channels that estradiol regulates is the epithelial sodium channel, or ENaC, which controls the final step of sodium reabsorption in the collecting ducts. Research has shown that estradiol actually reduces the activity of this channel, helping to prevent excessive sodium retention and thereby keeping systolic blood pressure in check.¹⁶ However, estradiol also increases the release of vasopressin (the hormone that tells your kidneys to retain water) and reduces fractional sodium excretion during fluid loading. In a study of postmenopausal women given estradiol, sodium excretion dropped significantly, suggesting that increased renal sodium reabsorption was a major contributor to fluid retention during high-estrogen states.¹⁷

These kidney effects pull in somewhat opposite directions: estradiol downregulates one sodium channel but enhances overall sodium reabsorption through other mechanisms. The net result in most women is mild fluid retention that does not translate into a meaningful blood pressure increase, though it helps explain why some individuals do experience bloating or a small rise in pressure when starting estrogen therapy.

Very High Estradiol Levels During Fertility Treatment

One scenario where estradiol levels can spike far above anything seen in normal physiology is during controlled ovarian stimulation for IVF. When the ovaries produce many follicles at once, estradiol can surge past several thousand picograms per milliliter, well above normal peak levels. This is a different situation from taking a standard hormone therapy dose.

When peak estradiol during ovarian stimulation exceeded roughly 3,450 pg/mL, women were nearly five times more likely to develop preeclampsia, a dangerous pregnancy complication defined by high blood pressure and organ damage.¹⁸ Adverse placental outcomes, including preeclampsia, increased when peak estradiol rose above 3,000 pg/mL and continued rising in a roughly linear fashion as levels climbed beyond 5,000 pg/mL.¹⁹

A preliminary study found that all seven cases of preeclampsia in their cohort occurred among women who had fresh embryo transfers during cycles with elevated peak estradiol. When embryos were cryopreserved and transferred in a later cycle with a more normal hormonal environment, no cases of preeclampsia occurred.²⁰ This strongly suggests that the supraphysiological estradiol levels themselves, rather than some other aspect of IVF, contribute to the blood pressure and placental problems. It is worth stressing that these estradiol levels are far higher than anything produced by hormone therapy patches or pills.

Estrogen Therapy in Transgender Women

Transgender women receiving estradiol as part of gender-affirming hormone therapy offer another window into how estrogen affects blood pressure. A systematic review covering ten studies and 661 transgender women found surprisingly mixed results. Three studies showed systolic blood pressure rising by 7 to 18 mmHg, while three others showed it falling by 3 to 10 mmHg. Most studies found no significant change in diastolic pressure.²¹

The anti-androgen medication taken alongside estradiol appears to be a factor. A five-year follow-up study of young transgender women found that the overall rate of developing hypertension looked low, but the choice of androgen blocker made a big difference. Among those taking cyproterone acetate, the incidence of hypertension was about 5%, compared with under 1% among those using other anti-androgens. The adjusted hazard ratio was striking enough that the authors flagged the cyproterone acetate group as a distinct risk category.²² So when blood pressure rises in transgender women on estrogen, the anti-androgen or other aspects of the regimen may be a bigger factor than the estradiol itself.

Genetics Shape Your Response

Not everyone’s blood vessels respond to estradiol in the same way, and part of the variation appears to be genetic. The genes coding for estrogen receptors come in different variants, and some of those variants are associated with higher blood pressure. In a study of postmenopausal Japanese women, those carrying a particular version of the estrogen receptor beta gene had systolic blood pressure averaging about 10 mmHg higher than women without that variant.²³ A separate study found sex-dependent associations between estrogen receptor gene variants and blood pressure in both men and women, with different variants affecting systolic versus diastolic pressure.²⁴

This genetic variability helps explain why population-level studies often show neutral or beneficial effects of estradiol on blood pressure, while individual women sometimes experience a clear rise. Your estrogen receptor profile influences how efficiently your blood vessels respond to the hormone’s vasodilatory signals. If your receptors are less responsive, you may not get the full blood pressure benefit and could be more susceptible to the fluid-retaining or RAAS-activating effects.

What Happens During the Normal Menstrual Cycle

If estradiol had a major effect on blood pressure, you might expect to see blood pressure fluctuate noticeably across the menstrual cycle as estrogen levels rise and fall. A study measuring central arterial pressure waveforms during the menstrual cycle found that while estradiol, progesterone, and renin-angiotensin system hormones were all higher in the luteal phase, central and peripheral blood pressures and measures of arterial stiffness were unchanged between cycle phases.²⁵ The body’s compensatory mechanisms appear to buffer against the blood pressure effects of normal hormonal cycling, keeping readings stable even as estradiol swings from low to high and back again every month.

Estradiol’s Effects in Men

Men also produce estradiol in small amounts, and there is evidence that low-dose estrogen therapy can benefit male blood pressure under certain circumstances. In hypogonadal men given low-dose estrogen, both systolic and diastolic blood pressures decreased. The researchers concluded that the treatment was well tolerated and appeared to improve vascular function through several mechanisms, including enhancing baseline nitric oxide release and dampening the blood vessel constricting effects of angiotensin II and norepinephrine.²⁶

In men with prostate cancer treated with transdermal estradiol, arterial blood flow increased significantly over time. Arterial compliance initially decreased but normalized after twelve months of therapy.²⁷ These findings reinforce the idea that estradiol’s blood pressure effects are not exclusive to women, and that the hormone’s vasodilatory properties work across sexes when the dose and route are appropriate.

Soy Isoflavones and Plant Estrogens

Given estradiol’s vasodilatory effects, a reasonable question is whether plant-based estrogen-like compounds (phytoestrogens) found in soy and other foods can lower blood pressure. A randomized controlled trial gave daily soy isoflavone supplements to menopausal women with borderline-high blood pressure and found no significant differences in 24-hour ambulatory blood pressure, forearm blood flow, vascular resistance, or artery elasticity compared with placebo.²⁸ Phytoestrogens bind weakly to estrogen receptors compared with estradiol, so it is not surprising that their blood pressure effects are far more modest, if present at all. The cardiovascular benefits sometimes attributed to soy-rich diets likely come from the food matrix as a whole rather than from estrogenic activity alone.

Aortic Stiffness and Regional Differences

Estradiol’s effects on blood vessels are not uniform throughout the body. An animal study found something counterintuitive: removing the ovaries actually decreased aortic stiffness, and giving estrogen back increased it again. Estrogen-treated rats also showed left ventricular hypertrophy and increased pulse pressure, both markers associated with cardiovascular strain. However, the same estrogen treatment enhanced the ability of smaller vessels in the hindquarters to dilate, while having no such effect on carotid vessels.²⁹ In hypertensive postmenopausal women, though, a twelve-week course of estradiol did not significantly change aortic pulse-wave velocity, a measure of large-artery stiffness.³⁰ The regional heterogeneity of estrogen’s vascular effects is an active area of research and may eventually help clinicians predict which patients will respond well to hormone therapy and which will not.